CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, breast cancer surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
  
  LEARNING OBJECTIVES

  • Appreciate the key clinical variables that affect the use of preoperative therapy and the selection of therapeutic regimens for patients with HER2-overexpressing localized breast cancer (BC), and integrate this information into treatment decision-making.
  • Apply available research evidence to individualize the selection and use of adjuvant systemic therapy for patients with HER2-positive localized BC who received neoadjuvant treatment.
  • Evaluate published research data to guide the selection and duration of adjuvant and/or extended-adjuvant therapy for patients with HER2-overexpressing localized BC.
  • Implement a long-term clinical plan for the management of advanced HER2-positive BC, incorporating existing and recently approved targeted agents and regimens.
  • Design an optimal approach to the clinical care of patients with HER2-positive BC and CNS metastases, considering the implications of prior therapeutic exposure, symptomatology and other factors.
  • Recognize common and rare side effects associated with approved and investigational anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive BC.
  • Assess ongoing clinical research studies evaluating novel agents and treatment strategies under development for HER2-positive BC, and counsel patients regarding the potential benefits of trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Carey K Anders, MD
  Professor of Medicine
  Medical Director of the Duke Center for Brain and Spine Metastases
  Duke Cancer Institute
  Durham, North Carolina
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Eisai Inc, Elucida Oncology Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Novartis, Seagen Inc; Contracted Research: G1 Therapeutics, Lilly, Merck, Nektar, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Tesaro, A GSK Company, The Zion Pharma; Royalties: Jones and Bartlett Learning.
  
  Erika Hamilton, MD
  Director, Breast and Gynecologic Research Program
  Sarah Cannon Research Institute
  Nashville, Tennessee
  
  Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Lilly, Mersana Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc; Consulting Agreement: Flatiron Health; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ArQule Inc, AstraZeneca Pharmaceuticals LP, BerGenBio ASA, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, FUJIFILM Pharmaceuticals USA Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Hutchison MediPharma, Immunomedics Inc, InventisBio, Kadmon Corporation, Leap Therapeutics Inc, Lilly, Lycera, MacroGenics Inc, Mallinckrodt Pharmaceuticals, Marker Therapeutics Inc, Medivation Inc, a Pfizer Company, Mersana Therapeutics, Merus BV, Novartis, NuCana, OncoMed Pharmaceuticals Inc, Pfizer Inc, PharmaMar, Radius Health Inc, Regeneron Pharmaceuticals Inc, Rgenix, Seagen Inc, Stemcentrx, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TetraLogic Pharmaceuticals, Verastem Inc, Zymeworks; Travel/Accommodations/Expenses (payment or reimbursement of actual expenses): Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Eisai Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genzyme Corporation, Guardant Health, Helsinn Healthcare SA, Heron Therapeutics, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Sysmex Corporation, Tesaro, A GSK Company.
  
  Sara Hurvitz, MD
  Professor of Medicine
  David Geffen School of Medicine at UCLA
  Director, Breast Cancer Clinical Research Program
  Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
  Santa Monica, California
  
  Consulting Agreement (Stock Investment): NKMax America; Contracted Research: Ambrx Inc, Amgen Inc, Arvinas, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Dignitana, Genentech, a member of the Roche Group, GlaxoSmithKline, Immunomedics Inc, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Pfizer Inc, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Sanofi Genzyme, Seagen Inc, Zymeworks; Paid Travel: Lilly; Stocks (Spouse): IDEAL IMPLANT, ROMTech.
  
  Mark D Pegram, MD
  Susy Yuan-Huey Hung Endowed Professor of Oncology
  Director, Clinical and Translational Research Unit
  Associate Dean for Clinical Research Quality
  Stanford University School of Medicine
  Associate Director for Clinical Research
  Stanford Comprehensive Cancer Institute
  Stanford, California
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, MacroGenics Inc, Merck, Novartis, Odonate Therapeutics, Pfizer Inc, Puma Biotechnology Inc, Samsung Bioepis, Seagen Inc, Zymeworks; Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Pfizer Inc, Zymeworks; Data and Safety Monitoring Board/Committee: Roche Laboratories Inc; Employment (Spouse): Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company.
  
  Sara M Tolaney, MD, MPH
  Associate Director, Susan F Smith Center for Women’s Cancers
  Director of Clinical Trials, Breast Oncology
  Director of Breast Immunotherapy Clinical Research
  Senior Physician
  Breast Oncology Program
  Dana-Farber Cancer Institute
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Athenex, Bristol-Myers Squibb Company, Celldex Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, G1 Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Kyowa Kirin Co Ltd, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, OncoPep, Pfizer Inc, Puma Biotechnology Inc, Samsung Bioepis, Sanofi Genzyme, Seagen Inc, Silverback Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, Pfizer Inc, Sanofi Genzyme, Seagen Inc; Data and Safety Monitoring Board/Committee: Odonate Therapeutics.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Puma Biotechnology Inc and Seagen Inc.
  
  Release date: February 2021
  Expiration date: February 2022